Extended Data Table 1.
Adverse events leading to treatment discontinuation during the first seven days from randomization
| Cloxacillin plus Fosfomycin (n = 104) | Cloxacillin alone (n = 110) | |
|---|---|---|
| Patients with adverse events leading to treatment discontinuation | 11 (10.6%) | 9 (8.2%) |
| Adverse events leading to treatment discontinuation* | 13 (11.3%) | 10 (10.6%) |
| Cardiac disorders | 1 | 1 |
| Gastrointestinal disorders | 5 | 1 |
| General disorders and administration site conditions | 1 | 0 |
| Hepatobiliary disorders | 1 | 0 |
| Infections and infestations | 0 | 1 |
| Investigations | 2 | 0 |
| Metabolism and nutrition disorders | 3 | 2 |
| Neoplasms benign, malignant and unspecified | 0 | 1 |
| Renal and urinary disorders | 0 | 2 |
| Respiratory, thoracic and mediastinal disorders | 0 | 1 |
| Skin and subcutaneous tissue disorders | 0 | 1 |
* Percentage computed with respect to the total number of adverse events (115 for cloxacillin plus fosfomycin and 94 for cloxacillin alone).